Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Mallinckrodt
Age
18–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Has biopsy-confirmed sarcoidosis meeting American Thoracic Society criteria ≥ 1 year at screening (Visit 1)
Has protocol-defined symptomatic pulmonary disease
Has been receiving a stable prednisone dose between 5 mg and 40 mg (or equivalent) for pulmonary sarcoidosis, for at least 4 weeks before screening, or a stable dose of another disease-modifying anti-sarcoidosis drug for at least 3 months before screening
Has lung function within protocol-defined parameters
You may not be if
Has at least a 10% change in forced vital capacity (FVC) on spirometry between Visits 1 and 2
Has pulmonary arterial hypertension requiring treatment
Has been treated with antitumor necrosis factor-α antibody within the past 3 months
Has any pulmonary condition that requires treatment, therefore impeding corticosteroid tapering
